Stability Indicating RP-HPLC Method for the Estimation of ORLISTAT in Bulk and Pharmeceutical Dosage Forms
More details
Hide details
Online publication date: 2019-04-25
Publication date: 2019-04-25
Eurasian J Anal Chem 2019;14(2):emEJAC191027
The current research goal was to develop a novel specific procedure for the quantitation of the Orlistat. The method development was done by using a High-Performance Liquid Chromatography (HPLC). The extensive method development was conducted to identify a right combination of chromatographic conditions and validated as per the regulatory guidelines. The current method overcome the disadvantages of other methods likewise UV and potentiometric titrations. The mixture of mobile phase A and B (50:50) used to elute the Orlistat in isocratic mode. The rapid run time of the method was accomplished by adjusting the flow rate of 2.0mL per minute along with L1-octadecyl chemistry column. The Orlistat peak was detected by using a sensitive Ultra violet detector at 205nm. The method was completely screened with all the key validation parameters likewise suitability, precision, selectivity, linearity, robustness and recovery. The purity threshold of more than 990 proves that the method is free from any possible interferences and the linearity was established at 5 different levels with a correlation coefficient 0.998. The overall %RSD (relative standard deviation) of mean recovery was 0.70%. The marketed commercial formulation of Orlistat capsules was tested on the developed method to confirm the suitability of the method for both bulk active substance and pharmaceutical formulations. Based on the experimental outcome method can be regarded as inventive, and specific to quantitate Orlistat. The developed method can be used directly to test the pharmaceutical formulations and drug substances. Further these methods can be modified to determine the impurities in drug substances and drug products.